Phase 4 N=150 Effects on the Pain of an Infiltration by Acid Hyaluronic Association and Corticoids Versus Only Corticoids in the Rhizarthrosis.
Rhizarthrosis
Primary: Analogical Visual Scale of Pain (VAS) — -1.66; -2.65 centimeter
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=98 Applying Num Vapocoolant Spray to Cervix Before Paracervical Block to Decrease Pain During Gynecology Procedures
Pain With Paracervical Block · Pain With Gynecology Procedure · Pain
Primary: Pain With Paracervical Block — 27; 20 units on a scale
Phase 4 N=785 Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users
Moderate to Severe Opioid-use Disorder
Primary: Maintenance Phase: Percentage of Responders for Weekly Opioid Use Over Weeks 20 to 38 — 44; 50 Participants — p=0.4819
Phase 4 N=210 Health Systems Reach Interventions Project
Smoking, Cigarette · Smoking Cessation
Primary: Number of Participants Who Initiate Treatment Over 1 Year of Study Enrollment — 0; 2; 1; 0 Participants
Phase 4 N=71 Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
Meningococcal Immunisation · Healthy Volunteers
Primary: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, Y, and W — 72.1; 100…
Phase 4 N=183 A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
Depressive Disorder, Major
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 88.0 percentage of participants
Phase 4 N=48 Defining Predictors of RT Response to Vedolizumab in IBD
Crohn Disease of Small Intestine
Primary: Radiological Response — 21; 16 participants
Phase 4 N=30 Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways Diseases
Chronic Cough · Eosinophilic Bronchitis · Asthma
Primary: Change From Baseline in 24-hour Cough Frequency at 14 Weeks — 17.0; 17.0; 12.6; 10.6 Coughs/hour — p=0.99
Phase 4 N=182 Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).
Advanced NSCLC
Primary: Percentage of Participants With Gene Alterations inTissue Detected by NGS — 139; 106; 47 Participants
Phase 4 N=45 Doxy-Post-exposure Prophylaxis
Sexually Transmitted Diseases
Primary: Doxycycline Concentrations in Rectal Tissues — 0.863; 2.193 µg/g
Phase 4 N=72 The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
Acute Coronary Syndrome
Primary: Assess Inflammatory Response to Intravenous Endotoxin — 167.53; 111.05; 254.92; 128.73 pg/ml
Phase 4 N=83 Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Mild Cognitive Impairment
Primary: California Verbal Learning Test II — 6.9; 6.2; 6.46; 5.10 units on a scale — p=0.048
Phase 4 N=5 Testing C-Raven, a Virtual Tobacco Cessation Intervention, in the Community
Tobacco Dependence
Primary: Acceptability and Feasibility as Assessed by the Number of Participants Who Complete Intervention and Surveys — 5; 5 Participants
Phase 4 N=399 Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study
Hiv
Primary: Proportion of Participants Who Did Not Complete the 28-day PEP Regimen — 114 Participants
Phase 4 N=400 Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings
Diabetes Mellitus, Type 1 · Type 1 Diabetes
Primary: Time-in-serious Hypoglycemia — 3.6; 3.4; 2.4; 3.8 percentage of time — p=0.43